e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Okamoto M., Hoshino T., Kitasato Y., Sakazaki Y., Kawayama T., Fujimoto K., Ohshima K., Shiraishi H., Uchida M., Ono J., Ohta S., Kato S., Izuhara K., Aizawa H.
Source:
Eur Respir J 2011; 37: 1119-1127
Journal Issue:
May
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Okamoto M., Hoshino T., Kitasato Y., Sakazaki Y., Kawayama T., Fujimoto K., Ohshima K., Shiraishi H., Uchida M., Ono J., Ohta S., Kato S., Izuhara K., Aizawa H.. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 2011; 37: 1119-1127
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Idiopathic pulmonary fibrosis - IPF
Source: Respipedia Article
Year: 2018
Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias
Source: Eur Respir J 2007; 29: 134-137
Year: 2007
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Histopathological assessment and classification
Source: Annual Congress 2006 - PG8 - Interstitial lung diseases: idiopathic interstitial pneumonias
Year: 2006
Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
KL-6/MUC1 in interstitial pneumonia
Source: Annual Congress 2005 - Lung-specific serum markers for interstitial lung diseases
Year: 2005
Histology and pathogenesis of usual interstitial pneumonia (UIP)
versus
nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006
Surfactant proteins in interstitial pneumonia
Source: Annual Congress 2005 - Lung-specific serum markers for interstitial lung diseases
Year: 2005
Interstitial fibrosis with a nodule
Source: Annual Congress 2007 - Thoracic Oncology Grand Round: an interactive session
Year: 2007
Clinical categorisation of idiopathic interstitial pneumonia
Source: Annual Congress 2005 - Idiopathic pulmonary fibrosis: new concepts in its pathogenesis and management
Year: 2005
Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Significance of connective tissue disease features in idiopathic interstitial pneumonia
Source: Eur Respir J 2012; 39: 661-668
Year: 2012
The classification, natural history and radiological/histological appearance of idiopathic pulmonary fibrosis and the other idiopathic interstitial pneumonias
Source: Eur Respir Rev 2008; 17: 108-115
Year: 2008
IGFBP-2 a new interesting target in IPF
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP)
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept